Brokers Offer Predictions for Olema Pharmaceuticals, Inc.’s FY2023 Earnings (NASDAQ:OLMA)
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) – Investment analysts at Capital One Financial issued their FY2023 earnings estimates for shares of Olema Pharmaceuticals in a report released on Thursday, February 22nd. Capital One Financial analyst N. Quibria anticipates that the company will earn ($2.22) per share for the year. Capital One Financial has a “Overweight” rating on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.14) per share. Capital One Financial also issued estimates for Olema Pharmaceuticals’ Q4 2023 earnings at ($0.56) EPS, Q1 2024 earnings at ($0.69) EPS, Q2 2024 earnings at ($0.52) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.68) EPS, FY2024 earnings at ($2.55) EPS, FY2025 earnings at ($2.55) EPS, FY2026 earnings at ($2.73) EPS and FY2027 earnings at ($2.63) EPS.
Separately, Citigroup began coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Olema Pharmaceuticals has a consensus rating of “Buy” and an average target price of $21.00.
Check Out Our Latest Stock Report on Olema Pharmaceuticals
Olema Pharmaceuticals Trading Up 0.1 %
Shares of NASDAQ:OLMA opened at $13.49 on Monday. The company has a market cap of $743.30 million, a price-to-earnings ratio of -5.81 and a beta of 2.20. Olema Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $17.79. The company has a 50-day moving average price of $13.33 and a 200-day moving average price of $12.77.
Insider Transactions at Olema Pharmaceuticals
In other news, major shareholder Biocapital Advisors L. Paradigm acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was acquired at an average price of $11.60 per share, for a total transaction of $1,160,000.00. Following the completion of the acquisition, the insider now owns 6,590,981 shares in the company, valued at $76,455,379.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Cyrus Harmon sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $12.57, for a total transaction of $314,250.00. Following the completion of the transaction, the director now owns 926,283 shares of the company’s stock, valued at approximately $11,643,377.31. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Biocapital Advisors L. Paradigm acquired 100,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, December 6th. The shares were bought at an average cost of $11.60 per share, with a total value of $1,160,000.00. Following the transaction, the insider now owns 6,590,981 shares in the company, valued at $76,455,379.60. The disclosure for this purchase can be found here. Corporate insiders own 23.50% of the company’s stock.
Hedge Funds Weigh In On Olema Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of OLMA. Royal Bank of Canada raised its holdings in Olema Pharmaceuticals by 682.4% in the 2nd quarter. Royal Bank of Canada now owns 2,801 shares of the company’s stock worth $25,000 after acquiring an additional 2,443 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter worth $28,000. Balyasny Asset Management LLC purchased a new position in shares of Olema Pharmaceuticals in the third quarter worth $33,000. Virtu Financial LLC purchased a new position in Olema Pharmaceuticals in the 4th quarter worth about $33,000. Finally, Citigroup Inc. purchased a new position in Olema Pharmaceuticals in the 1st quarter worth about $34,000. 88.00% of the stock is currently owned by institutional investors.
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
Featured Stories
Receive News & Ratings for Olema Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Olema Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
